



P0179 SeraQ Elecsys



REF **P0179**



The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance.



Table of contents

Intended Use..... 3

Key to Symbols Used 3

Principle of method 3

Traceability of antigen and antibody concentrations 4

Kit contents (materials provided)..... 4

Materials not provided 5

Storage Instructions 5

Warning and precautions 5

Reagent preparation 5

Analytical Performance Characteristics 6

Expected assay response values 8

Interpretation of Results 8

Limitations 13

References..... 14


Intended Use

P0179 SeraQ Elecsys is intended to be used on the Roche Elecsys® 8000 e602/e801 platforms in diagnostic and blood screening laboratories as an external run control in combination with the assays for the detection of hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus (anti-HCV) and antibodies to human immunodeficiency virus types 1 and 2 (anti-HIV 1/2) (see Table 1). P0179 SeraQ Elecsys is a multi-marker mixture of inactivated HBsAg, anti-HCV and anti-HIV-1 standards in defibrinated plasma giving a low reactive result in the Roche Elecsys® Assays. The run control is intended for testing in consecutive runs of the immunoassays over time by trained laboratory workers. By comparison of the sample to cut off (S/CO) values for the three markers found on P0179 SeraQ Elecsys one can monitor whether the analytical sensitivity of test runs is consistent. The run control should not be used to replace internal controls or calibrators in the test kits. The test result on the run control should not be used to reject the run or delay the release of test results on donor or patient samples. This product is used for performance evaluation only.


Table 1. Test kits covered by this run control

Equipment	Virus	Tests
cobas® 8000 e602/e801	Hepatitis B virus	Roche Elecsys® HBsAg II
	Hepatitis C virus	Roche Elecsys® Anti-HCV II
	Human immunodeficiency virus	Roche Elecsys® HIV combi PT 4th generation (Ag+Ab)


Key to Symbols Used




Manufacturer




Lot number




Catalogue number




Store below -20°C




Country of origin




Contains human blood derivatives




Expiry date




Number of controls




Caution



For IVD performance evaluation only



Unique device identification



Read instructions for use

Principle of method

A series of SeraQ multi-marker run controls has been designed for monitoring HBsAg, anti-HCV and anti-HIV-1 test performance. The run control tubes are barcoded and can be placed at random positions in sample racks of the blood screening device. The tubes are comparable in size to donor blood collection tubes. The run controls are designed to mimic naturally occurring serum specimens with low reactivity for HBsAg, anti-HCV and anti-HIV-1. The analytical sensitivity of test kits from different manufacturers varies and therefore for each combination of test kits a separate multi-marker run control has been designed. This SeraQ run control series includes the product P0179 SeraQ Elecsys for which the composition is optimised for use with the Roche Elecsys® test system. The P0179 SeraQ Elecsys run control is designed to generate assay response values (i.e.

S/CO ratios) for HBsAg, anti-HCV and anti-HIV-1 positioned in the low positive range of the assays. Routine use of external run controls enables laboratories to monitor day-to-day test performance and and *in-vitro* medical diagnostic device (IVD) IVD reagent lot variation. After approval by the Notified Body a summary of the safety and performance of the P0179 SeraQ Elecsys run control will be published at the EUDAMED website of the European Union¹.

Traceability of antigen and antibody concentrations

For each HBsAg, anti-HIV-1 and anti-HCV, an internal serum standard has been established² from which reference panels and run controls are prepared by gravimetrically recorded dilution steps. The undiluted S0001 standard for HBsAg is derived from the same purified heat-inactivated source material as is used for preparation of the 2nd WHO HBsAg adw2 (00/588) International Standard (IS)^{3,4}. Studies with the later established WHO international hepatitis B virus genotype reference panel showed that the heat-inactivation of HBsAg in the International Standard had little impact on the detectability in immuno-assays⁵. The HBsAg concentration in the run control has been set at 0.16 IU/mL based on the dilution factor of the HBsAg standard^{2,3}. During manufacturing of SeraQ run controls the measurable HBsAg concentration reduces to a certain extent depending on the test method. One IU of heat inactivated HBsAg was found to be equivalent to 0.67 nanogram (ng) of HBsAg when historically calibrated against the first HBsAg standard established by the Paul Ehrlich Institute (1st PEI HBsAg standard), comparable to conversion factors of 0.58 and 0.71 reported in WHO collaborative studies^{3,4,6}. The S0001 HBsAg standard used for preparation of the SeraQ run controls has been instrumental in studies to establish the length of the pre-HBsAg infectious window period and the infectivity of HBsAg positive blood without detectable hepatitis B virus (HBV)-DNA^{7,8}. No unitage could be assigned to the internal standards for anti-HCV and anti-HIV-1 since international reference preparations are not available. The consistent concentration of the analytes in consecutive SeraQ run control batches is guaranteed by release testing against a reference batch of the run control kept frozen at -30°C. These reference batches are derived from the same undiluted internal standards that are used for manufacturing of the SeraQ run controls.

Kit contents (materials provided)

The run control contains human serum with 0.01% (w/v) Thimerosal as preservative and is provided in two formats as detailed in Table 2.

Table 2. Description of P0179 SeraQ Elecsys kit formats and contents

Cat. Code	GTIN/UDI-DI code [^]	Quantity run control	Tube size	Claimed sample volume	Secondary packaging
P0179/01	8718719833667	60 x 2.0 mL	10 mL	1.9 mL (+overfill)	60 tube rack in box
P0179/02	8718719833674	10 x 2.0 mL	10 mL	1.9 mL (+overfill)	10 tubes in bag

[^] Global Trade Item Number = Unique Device Identification - Device Identifier (UDI-DI) code

The basic UDI code (or Global Model Number (GMN)) of the P0179 SeraQ Elecsys run control is 871871983P0179F7.

To facilitate automation the run control is presented in a polypropylene tube with screw cap comparable in size to vacutainer tubes used for donor sample collection. In addition, the label includes a barcode identifying the product, sequential batch number and multi-

marker: MM. The barcode of each run control tube can be read by the Roche cobas instruments.

Materials not provided

Pipetting devices in IVD test systems, a vortex instrument for thorough mixing of samples prior to use and a water bath of 37°C for quickly thawing of run control are not provided.

Storage Instructions

Store unopened tubes at or below -20°C. For each cobas instrument thaw one run control tube in a water bath of 37°C until ice clot has disappeared. After thawing, the run control tubes should be stored at 2°C to 8°C for no longer than one week.

Warning and precautions

P0179 SeraQ Elecsys run controls are prepared from serum standards, in which virus has been inactivated by *in vivo* validated methods applied in the plasma industry². Infectivity and inactivation data have been analysed to demonstrate absence of residual infectivity of HBV, HCV and HIV-1 in the run controls². The serum matrix in the run controls has been tested for infectious disease markers by serologic and molecular screening methods. However, no screening strategy can offer complete assurance that products derived from human blood cannot transmit undetected infectious agents. The run control should only be used by trained laboratory workers who are aware of the potential risk of infectious agents in human serum samples and take the necessary precautions.

- SeraQ run controls should be handled with the normal preventive measures in a serology laboratory^{9,10}.
- This product contains human plasma and traces of biological source material of non-human origin (bovine thrombin).
- The use of the run control in other assay configurations should be avoided and is not supported by the manufacturer.
- Wear disposable gloves when handling samples.
- Do not eat drink, smoke or apply cosmetics in areas where specimens are handled.
- Do not pipette by mouth.
- If skin or mucous membrane exposure occurs, immediately wash the area with copious amounts of water.
- Disinfect spills using a 0.5% hypochlorite solution (1:10 v/v household bleach) or equivalent disinfectant.
- Dispose unused or spilled materials according to the normal practices for biological waste disposal in your institution.
- If precipitates are visible, mix the run controls for 2 minutes thoroughly using a vortex instrument.
- Do not use run controls beyond one week storage at 2-8°C.
- Store run controls in an upright position.
- Validation of the diagnostic test results must be based on the specifications set by the manufacturer of the test kit and not be influenced by the test result on the run control.

Reagent preparation

- For first use of the run control thaw the tube quickly in a water bath at 37°C.

- Mix gently during thawing until contents are just thawed.
- Immediately after ice clot has disappeared remove the run control tube from the water bath.
- Before testing allow the run control tube to adapt to room temperature.
- Mix the run control tube thoroughly prior to use using a vortex instrument.
- Place the run control tube at the specified positions in the sample racks of the cobas 8000 system for regular donor or patient samples.
- Test on the Roche cobas 8000 platform with the assays mentioned in Table 1 according to the manufacturer's instructions
- Store the opened tube immediately after use at 2-8 °C (see storage instructions).

Analytical Performance Characteristics

SeraQ run controls have been designed by examination of the response curves on dilutions of the internal standards and as such relate to the analytical sensitivity of immunoassays. In the following paragraphs the essential analytical performance characteristics of SeraQ run controls are presented.

Dose response and analytical sensitivity

By analysing standard dilution series the relationship between S/CO values and concentration of the analyte can be established^{11,12}. Plotting Log transformed Elecsys S/CO values against Log concentration analyte using linear regression analysis enables calculation of correlation coefficients. Figures 1a, 1b and 1c show linear dose response relations in the Roche Elecsys® HBsAg, anti-HCV and HIVAb/Ag assays obtained after log transformation of dilution factor and S/CO values.

Figure 1a. Dose response in Elecsys HBsAg II assay. Log HBsAg S/CO values are plotted against log dilution ($r^2 = 0.99$).




Figure 1b. Dose response in Elecsys anti-HCV II assay. Log anti-HCV S/CO values are plotted against log dilution ($r^2 = 0.99$).





Figure 1c. Dose response in Elecsys HIV Ag/Ab assay. Log HIVAb/Ag S/CO values are plotted against log dilution ($r^2 = 0.999$). Run control level was originally set at 1:200,000 dilution of the S0071 standard but was later changed to 1:89,000.



Expected assay response values

The expected results for the P0179 SeraQ Elecsys run control are follows:

1. HBsAg range S/CO ratio: 2.5 – 4.1
2. anti-HCV range S/CO ratio: 1.5 – 3.5
3. anti-HIV range S/CO ratio: 2.5 – 5.5

Each Elecsys reagent lot appears to have its own dose response curve and distribution of S/CO values on SeraQ run controls. This depends on the analytical sensitivity of the Roche Elecsys reagent lots that are in use. Thus, it cannot be guaranteed that the assay response values will always fall within these ranges. P0179 SeraQ Elecsys run control serves as an independent standard for monitoring consistent analytical sensitivity of Elecsys reagent lots over time.

Interpretation of Results

Calculations

Subsequent test runs can be analysed by appropriate statistical approaches on the S/CO ratios obtained on the external control samples. A software system (DataQ Analytics) is available via the website www.bioqcontrol.com for entering S/CO values and generating a statistical report with the following calculations for preparing a Levey-Jennings Chart:

Transforming assay response values

To obtain the test kit batch specific reference values for each marker, an initial collection of at least 30 consecutive test results is required. Upon collecting additional data the chart characteristics may be updated.

- The S/CO values for HBsAg, anti-HCV and anti-HIV are 'log normally' distributed. For the Elecsys assays one should use the logarithm of S/CO ratios for calculation of the geometric mean and predictive interval (pred. int.).
 - Calculate from each measurement the log S/CO value.
 - Calculate average and standard deviation on this log transformed values; Average (log) and Standard Deviation (log).
 - Calculate the (geometric) mean in S/CO ratio by taking the anti-log value of the Average (log).
 - Calculate Student-t-values belonging to the 95% and 99% pred. int. for different number of observations (n) (Table 3).
 - Calculate the 95% and 99% pred. int. (log) as follows:

99% Lower limit (log):	Average (log) – (99%) Student-t-Value x Standard Deviation (log)
95% Lower limit (log):	Average (log) – (95%) Student-t-Value x Standard Deviation (log)
95% Upper limit (log):	Average (log) + (95%) Student-t-Value x Standard Deviation (log)
99% Upper limit (log):	Average (log) + (99%) Student-t-Value x Standard Deviation (log)
 - Take the anti-log values for calculating the predictive limits in S/CO ratio. To visualize the individual S/CO values make a Levey-Jennings control chart on a linear scale. S/CO ratios plotted on a linear scale depict the upper 95% and 99% predictive limits at greater distance from the geometric mean S/CO value than the lower predictive limits (see examples in Figure 2a, b and c).

Levey-Jennings chart

Figure 2a, 2b and 2c show examples of Levey-Jennings charts for different Elecsys assays on the P0179 SeraQ Elecsys run control as can be obtained from the statistical reports by the DataQ Analytics software system. The Levey-Jennings chart is a graph in which quality control results are plotted over subsequent test runs in time to give a visual indication when a laboratory test is (not) working well. The data points for each test run

in the scatter plots of Figure 2a-c show the distance from the geometric mean S/CO ratio (green line in graph) which is the expected response level for the run control. The orange and red lines represent the 95% and 99% predictive intervals, respectively. The data represents individual measurements of one laboratory using two instruments.

Table 3. Relation of Student t value and numbers of runs (n) to calculate predictive intervals.

Runs (n)	t-value at 95% pred. int.	t-value at 99% pred. int.
10	2.262	3.250
20	2.093	2.861
30	2.045	2.756
Infinite	1.960	2.576

Infinite equals the normal distribution

Figure 2. Levey-Jennings charts of P0179 SeraQ Elecsys run control results in Roche Elecsys assays one laboratory using two cobas e801 instruments. The average (green line) and 95% and 99% predictive intervals (orange and red lines) are log transformed as explained in the text.

Figure 2a. Elecsys HBsAg II Assay




Figure 2b. Elecsys anti-HCV II Assay.





Figure 2c. Elecsys Combi PT 4th generation (Ag+Ab) Assay



Interpretation

Knowing the 95% and 99% predictive intervals for generating a Levey-Jennings chart one can use Nelson rules¹³ to interpret values outside the predictive limits for identifying trends and aberrant results. The statistical report generated by the DataQ Analytics system (on the website www.bioqcontrol.com) identifies these trends and outliers for the laboratory requesting the report.

- Negative or positive trends resulting from gradual changes in test performance and not reported by the internal kit controls and/or alert systems in the test robot, are indicative for a lack of maintenance, the need for recalibration of equipment, or

degradation of reagents. These are systematic errors. In case a trend is recognised, the laboratory is encouraged to identify the root cause of the deviation.

- Aberrant results like a negative response on the run control or a result outside the 99% predictive interval are indicative for (incidental) random errors that need further investigation to identify the root cause. The identification of the root cause of aberrant results is beyond the scope of the intended use of the run controls.
- Differences between S/CO values of laboratories could be attributed to different reagent lots or run control batches that are in use. The statistical report that can be obtained from the DataQ Analytics system (available on www.bioqcontrol.com) compares the assay response values on different lab instruments, test reagent lots and run control batches.

Roche Elecsys assay response values on P0179 SeraQ Elecsys run control

Table 4 gives an example of results obtained within the same Elecsys reagent lots. When a new reagent lot is introduced the values in Table 4 need to be reassessed (see Interpretation of Results).

Table 4. Roche Elecsys Assay response values on P0179 SeraQ Elecsys run control reported by one laboratory over a period of ten months

Elecsys Assay	n	geomean S/CO	95% pred. int. S/CO	99% pred. int. S/CO
HBsAg	2361	3.38	2.86 – 3.99	2.71 – 4.21
Anti-HCV	2350	3.07	2.82 – 3.34	2.75 – 3.43
HIV Ab/Ag	2310	3.05	2.71 – 3.43	2.61 – 3.56

Variation in immunoassay reagent lots and run control batches

Variation in S/CO ratio on run controls reflects the difference in analytical sensitivity of assay runs and reagent lots. Different batches of SeraQ run controls are prepared from the same serum standards. Therefore, the composition of the multi-marker run controls is consistent from batch-to-batch. Multi-variance analysis shows that test reagent lots are a larger source of variation in S/CO values than run control batches. Table 5 shows an example of such a comparison of the Elecsys anti-HCV II Assay S/CO response values obtained with different reagent lots and P0179 SeraQ Elecsys run control batches tested by two laboratories over a six-year observation period.

Table 5. Geomean Elecsys anti-HCV S/CO ratios (and 95% CI) found with different batches of P0179 SeraQ Elecsys run control and Elecsys reagent lots

Batch SeraQ run control	Test Reagent Lot Elecsys	n	Geomean (95% CI)	Year
B4179-001	283259	8	2.29 (2.20-2.39)	2018
	295208	22	1.90 (1.87-1.92)	2018
B4179-002	33746601	8	2.13 (2.10-2.16)	2018
B4179-003	33746601	7	2.17 (2.14-2.19)	2019
	35144401	23	2.29 (2.25-2.32)	2019
B4179-004	400145	30	2.38 (2.36-2.41)	2021
	641358	808	3.00 (2.99-3.00)	2023
	692256	494	3.20 (3.19-3.22)	2023
B4179-005	520162	15	2.87 (2.83-2.90)	2021
B4179-006	692256	178	3.20 (3.19-3.22)	2023
	705668	695	3.06 (3.06-3.07)	2023
B4179-007	705668	162	2.99 (2.98-3.01)	2023

Limitations

- SeraQ run controls were designed for monitoring the analytical performance of serologic test systems. They cannot be used to evaluate the diagnostic sensitivity of the assays.
- The run control must not be substituted for the mandatory controls or calibrators provided with IVD test kits for calculating the cut off and/or criteria for releasing test results.
- The response values on the run controls should not be used to release or reject the test run but can be used as an aid in the assessment of analytical performance.
- The expected S/CO values and 99% predictive intervals have been established with a limited number of Elecsys reagent lots. It cannot be guaranteed that S/CO values obtained with new reagent lots will always fall within these limits.
- Although the batch-to batch composition of SeraQ run controls is consistent some variation in the measurable potency of the serum standards in the run control batches cannot be avoided due to matrix effects and other manufacturing variables.

References

1. Summary of safety and performance (SSP) of P0179 SeraQ Elecsys run control. European Commission. To be published at EUDAMED – European Database on Medical devices.
2. Lelie PN, Van Drimmelen A.A.J. Preparation of inactivated viral standards: Safety assessment of quality control samples for viral serology and NAT assays in blood screening laboratories. BioQControl document number CE4006. www.bioqcontrol.com
3. Schüttler GG, Wend UC, Faupel FM, Lelie PN, Gerlich HW. J Antigenic and physiochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). J Clin Virol 2010;47:238-42
4. Ferguson M, Heath A, Lelie N, Nübling M, Nick S, Gerlich W, et al. WHO Working Group on Hepatitis and HIV Diagnostic Kits. Report of a collaborative study to (1) assess the suitability of a candidate replacement International Standard for HBsAg and a reference panel for HBsAg and (2) to calibrate the candidate standard in IU. 2003. <http://www.who.int/bloodproducts/cs/en/031987.pdf>.
5. Chudy M, Scheiblaue H, Hanschmann H-M, Kress J, Nick S, Wend U, Schüttler C, Nübling CM, Gerlich WH. Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel. J Clin Virol. 2013;58:47-53
6. Gerlich W. H., Thomssen R. (1975) Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume. Dev. Biol Stand 1975;30:78-87
7. Van Drimmelen H, Lelie PN, Early dynamics of hepatitis B virus (HBV-DNA) and surface antigen (HBsAg) in ramp-up phase of viremia: Implications for performance evaluation of blood screening assays. Viruses 2022, 14, 1942 <https://doi.org/10.3390/v14091942>
8. Ekiaby ME, Tanaka J, Van Drimmelen H, Allain J-P, Lelie N. Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors? J Viral Hepat. 2022;29:330-339. doi:10.1111/jvh.13666.
9. Centers for Disease Control (CDC). Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988; 37:377-388.
10. Centers for Disease Control (CDC). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989; 38(S-6): 1-36.
11. Plikaytis BD, Turner SH, Gheesling LL, Carlone GM. Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J Clin Microbiol. 1991;29(7):1439-46
12. Bank HL. A quantitative enzyme-linked immunosorbent assay for rat insulin J Immunoassay. 1988; 9(2):135-58.
13. Nelson LS, "The Shewhart Control Chart—Tests for Special Causes". Journal of Quality Technology 1984;16, no. 4: 238-239



Biologicals Quality Control B.V.
Droogmakerij 31h
1851 LX Heiloo
The Netherlands

Tel: +31 (0)72 2020 730
Website: www.bioQControl.com

KI4179
V 4.1 January 2025